Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2020 | Update on momelotinib for myelofibrosis

Abdulraheem Yacoub • 18 Aug 2020
Texas MPN Workshop 2020
Anemias Myelofibrosis Myeloproliferative Neoplasms Momelotinib Ruxolitinib
MOMENTUM SIMPLIFY-1

Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, MO, updates us on the clinical use of momelotinib, a JAK1/JAK2 inhibitor in patients with myelofibrosis, including the results of the SIMPLIFY-1 study (NCT01969838), evaluating momelotinib against ruxolitinib in patients with myelofibrosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Abdulraheem Yacoub

2:06
Parsaclisib plus ruxolitinib in myelofibrosis: a promising strategy for treatment-naive patients
Abdulraheem Yacoub • 26 Aug 2022
2:42
The management of advanced phase MPNs
Abdulraheem Yacoub • 26 Aug 2022
4:15
The latest data on momelotinib for MPNs
Abdulraheem Yacoub • 10 Aug 2021
4:11
Novel therapies and combinations for myelofibrosis patients
Abdulraheem Yacoub • 10 Aug 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:45
A 2-year analysis of the EBMT-SAAWP RACE trial: eltrombopag in aplastic anemia
Antonio Risitano • 16 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
The content of VJHemOnc is intended for healthcare professionals